Tarsus Pharmaceuticals Inc (TARS)
49.22
+2.72
(+5.85%)
USD |
NASDAQ |
Nov 14, 10:35
Tarsus Pharmaceuticals Debt to Equity Ratio: 0.2838 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.2838 |
| March 31, 2024 | 0.1088 |
| December 31, 2023 | 0.1514 |
| September 30, 2023 | 0.139 |
| June 30, 2023 | 0.1666 |
| March 31, 2023 | 0.1414 |
| December 31, 2022 | 0.1007 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.0955 |
| June 30, 2022 | 0.087 |
| March 31, 2022 | 0.1286 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2021
0.2838
Maximum
Jun 2024
0.1002
Average
0.1047
Median
Debt to Equity Ratio Benchmarks
| Amicus Therapeutics Inc | 2.178 |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.4322 |
| IGC Pharma Inc | 0.0173 |
| NovaBay Pharmaceuticals Inc | -1.128 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 376.84M |
| Total Liabilities (Quarterly) | 124.60M |
| Shareholders Equity (Quarterly) | 252.25M |
| Current Ratio | 7.031 |
| Net Debt Paydown Yield | -0.91% |